- Home
- SYBT vs VRDN Comparison
SYBT vs VRDN Comparison
Compare SYBT & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SYBT | VRDN |
|---|---|---|
| Founded | 1904 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2009 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SYBT | VRDN |
|---|---|---|
| Price | $76.31 | $17.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $76.00 | $35.46 |
| AVG Volume (30 Days) | 167.3K | ★ 1.6M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | ★ 22.11 | N/A |
| EPS | ★ 1.24 | N/A |
| Revenue | ★ $23,406,000.00 | $5,706,000.00 |
| Revenue This Year | $17.31 | $13.73 |
| Revenue Next Year | $9.32 | $279.00 |
| P/E Ratio | $61.17 | ★ N/A |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $61.51 | $13.18 |
| 52 Week High | $83.83 | $34.29 |
Technical Indicators
Market Signals| Indicator | SYBT | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 62.64 | 57.28 |
| Support Level | $68.40 | $15.58 |
| Resistance Level | N/A | $18.05 |
| Average True Range (ATR) | 1.93 | 0.74 |
| MACD | 0.19 | 0.16 |
| Stochastic Oscillator | 76.42 | 71.53 |
Price Performance
Historical ComparisonAbout SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank holding company providing commercial banking and wealth management services. Its Commercial Banking segment offers loan and deposit products to consumers and businesses, including retail and mortgage lending, deposit services, online and mobile banking, private banking, commercial and real estate lending, treasury and merchant services, international and correspondent banking, credit cards, and brokerage services through a third-party broker-dealer. Its Wealth Management and Trust (WM&T) segment provides investment management, financial and retirement planning, trust and estate services, and retirement plan management, with WM&T revenue distinguishing the company from similarly sized community banks.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.